Figure 3

Outcome of gene transfer with ss or scAAV1 in LS mice. LS mice were injected i.m. with 10¹¹ vg of ss or scAAV1-CMV-hF.IX (n = 4/group). Plasma was collected 1, 2, and 4 weeks post-injection. (A) Circulating hF.IX levels were measured by ELISA. (B) Anti-hF.IX IgG1 levels in plasma were measured by ELISA. (C) Bethesda titer. One BU represents the inhibition of 50% of clotting activity. (D) Splenocytes were harvested four weeks post-injection and restimulated with media alone, the CD8 epitope of hF.IX, or SEB, and IFN-γ spot-forming units (per 10⁶ cells) were measured by ELISPOT. Measurements were performed on individual animals. (E) Circulating hF.IX levels in C57BL/6 RAG^-/- mice 2 weeks post-injection with ss or scAAV1-CMV-hF.IX (n = 4/group). Data points are averages ± SEM. Results are representative of at least two independent experiments. * P < 0.05, *** P < 0.001, ns = not significant.